High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting that activation of MEK/ERK is critical for their survival. However, based on preclinical data, MEK inhibitors are unlikely to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Jinyang, Jacob, Sheeba, Kurupi, Richard, Dalton, Krista M., Coon, Colin, Greninger, Patricia, Egan, Regina K., Stein, Giovanna T., Murchie, Ellen, McClanaghan, Joseph, Adachi, Yuta, Hirade, Kentaro, Dozmorov, Mikhail, Glod, John, Boikos, Sosipatros A., Ebi, Hiromichi, Hao, Huaixiang, Caponigro, Giordano, Benes, Cyril H., Faber, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353975/
https://www.ncbi.nlm.nih.gov/pubmed/35905710
http://dx.doi.org/10.1016/j.celrep.2022.111095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353975/
https://www.ncbi.nlm.nih.gov/pubmed/35905710
http://dx.doi.org/10.1016/j.celrep.2022.111095

Ejemplares similares